A new analysis of Medicare data is shedding light on the significant human and economic burden of treatment-resistant depression, a condition that experts say affects millions of Americans and contributes to higher healthcare spending, increased hospitalizations and years of unnecessary suffering.
The findings were discussed during this week’s episode of the Health Policy Podcast featuring Mark Desmarais, principal at Health Management Associates, and Dr. William Sauvé, chief medical officer at Osmind.
Treatment-resistant depression, commonly referred to as TRD, is generally defined as depression that does not respond to at least two separate medication treatments. While many patients eventually find relief, others cycle through multiple therapies over the course of years without achieving remission.
Desmarais said a new report analyzing Medicare administrative claims data found that beneficiaries with treatment-resistant depression incur approximately $8,000 more in annual healthcare costs than patients whose depression is effectively managed.
“The individuals with TRD use more healthcare services, including hospital visits and medications,” Desmarais said during the podcast. “This is not just a personal issue; it has significant economic ramifications for the Medicare program.”
The report examined healthcare utilization patterns among Medicare beneficiaries and found that treatment-resistant depression is associated with increased use of medical services and higher overall spending.
Beyond the financial impact, experts said the condition can take a substantial toll on patients’ daily lives, careers and long-term health.
Sauvé said treatment-resistant depression often becomes a chronic condition that can persist for decades, affecting cognitive function, personal relationships and workplace productivity.
“Patients suffering from TRD often experience decades of chronic illness, which can exacerbate their condition and lead to additional health complications,” Sauvé said. “The longer effective care is delayed, the more severe the consequences can be.”
He noted that while the clinical definition of treatment-resistant depression typically involves failure to respond to two medication trials, many patients ultimately undergo far more treatment attempts before receiving effective care.
“In practice, many patients undergo eight or more trials over several years without achieving remission,” Sauvé said.
The discussion also highlighted broader challenges facing the nation’s mental health system.
According to Sauvé, demand for mental health services has grown substantially in recent years, with an estimated 60 million Americans potentially needing treatment. At the same time, the United States has roughly 50,000 practicing psychiatrists, creating a gap between patient needs and available care.
The shortage can be particularly problematic for patients with complex or treatment-resistant conditions that require specialized interventions.
Another challenge, both experts said, is the prior authorization process used by many insurers for certain mental health treatments.
Sauvé described prior authorization requirements as a significant administrative burden that can delay access to care for patients already struggling with severe depression.
“Prior authorization is a massive administrative challenge that can take weeks to resolve,” Sauvé said. “During this time, patients continue to struggle with their illness, which can lead to crises that require hospitalization.”
Delays in treatment can worsen symptoms, increase the likelihood of emergency care and contribute to higher healthcare costs, according to the discussion.
Desmarais said policymakers should consider reforms that improve access to effective therapies for treatment-resistant depression, arguing that earlier intervention could produce both clinical and economic benefits.
“Policymakers should create pathways that facilitate access to effective treatments for TRD,” Desmarais said. “This would benefit not just those patients but the healthcare system as a whole.”
Sauvé similarly argued that healthcare providers should move more quickly to alternative treatment options when standard approaches fail.
“We need to treat patients aggressively and not let them linger in ineffective treatments,” Sauvé said. “The cost of inaction is far greater than the cost of providing effective care early on.”
Both experts said addressing treatment-resistant depression will require a combination of improved access to care, workforce expansion and policy changes aimed at reducing barriers to treatment.
As mental health needs continue to rise nationwide, they argued that improving outcomes for patients with treatment-resistant depression could yield benefits not only for individuals and families but also for the healthcare system that bears much of the financial burden.
